Arcadia Biosciences (NASDAQ:RKDA) Upgraded to Sell at ValuEngine

ValuEngine upgraded shares of Arcadia Biosciences (NASDAQ:RKDA) from a strong sell rating to a sell rating in a research report sent to investors on Thursday, ValuEngine reports.

Separately, HC Wainwright reissued a buy rating and issued a $14.00 price target on shares of Arcadia Biosciences in a research note on Monday, December 23rd.

NASDAQ RKDA opened at $5.26 on Thursday. The business’s 50-day moving average is $5.54 and its 200 day moving average is $4.93. The stock has a market capitalization of $45.48 million, a PE ratio of -1.32 and a beta of -2.94. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.58 and a quick ratio of 5.27. Arcadia Biosciences has a 1 year low of $1.82 and a 1 year high of $10.40.

Arcadia Biosciences (NASDAQ:RKDA) last issued its quarterly earnings data on Wednesday, November 6th. The basic materials company reported ($2.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($1.27). The business had revenue of $0.39 million during the quarter, compared to the consensus estimate of $0.31 million. Arcadia Biosciences had a negative return on equity of 198.10% and a negative net margin of 1,938.76%. As a group, equities research analysts anticipate that Arcadia Biosciences will post -3.61 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in RKDA. Citadel Advisors LLC purchased a new position in Arcadia Biosciences in the second quarter worth about $32,000. Cambridge Investment Research Advisors Inc. bought a new position in shares of Arcadia Biosciences during the second quarter valued at $34,000. Squarepoint Ops LLC bought a new position in shares of Arcadia Biosciences during the third quarter valued at $124,000. Sabby Management LLC boosted its position in shares of Arcadia Biosciences by 150.0% during the third quarter. Sabby Management LLC now owns 50,000 shares of the basic materials company’s stock valued at $234,000 after buying an additional 30,000 shares during the last quarter. Finally, Morgan Stanley boosted its position in shares of Arcadia Biosciences by 162,800.0% during the second quarter. Morgan Stanley now owns 81,450 shares of the basic materials company’s stock valued at $250,000 after buying an additional 81,400 shares during the last quarter. Institutional investors and hedge funds own 7.80% of the company’s stock.

About Arcadia Biosciences

Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.

Read More: Cash Flow

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.